Pacritinib

Cellenkos® enters into Sponsored Research Agreement with Icahn School of Medicine at Mount Sinai, New York.

Retrieved on: 
Monday, April 1, 2024
Research, Pacritinib, JAK2, Bone marrow, Blood transfusion, CXCR4, Inflammation, Patient, University, Ruxolitinib, Clinical trial, CXCL12, Fedratinib, Safety, Pancreatic serous cystadenoma, University of California, Davis, MD Anderson Cancer Center, Albert Einstein Israelite Hospital, Pharmaceutical industry

Research exploring CK0804 (CXCR4-enriched, allogeneic, cord blood-derived T-regulatory cells) for treatment of myelofibrosis patients.

Key Points: 
  • Research exploring CK0804 (CXCR4-enriched, allogeneic, cord blood-derived T-regulatory cells) for treatment of myelofibrosis patients.
  • This research will be conducted under the guidance of Ronald Hoffman, MD, Albert A. and Vera G. List Professor of Medicine and Director of the Myeloproliferative Disorders Research Program at The Tisch Cancer Institute- Mount Sinai.
  • CK0804 is a novel allogeneic, CXCR4 enriched, Treg cell therapy product that utilizes Cellenkos' proprietary CRANE® technology to generate disease specific products.
  • Dr. Ronald Hoffman serves as a paid consultant for Cellenkos.

Essential Thrombocythemia Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Imago BioSciences, Incyte, Karyopharm, Novartis, PharmaEssentia, Celgene, Kartos, Sierra Oncology

Retrieved on: 
Wednesday, August 30, 2023
GSK plc, Disease, Headache, Essential thrombocythemia, Bleeding, Prevalence, Conditional sentence, Hydroxycarbamide, Bone marrow, Genetic testing, Platelet, Petechia, Aspirin, Common, LAS, Bruise, Dizziness, Spleen, Novartis, Patient, Risk, Physiology, Plateletpheresis, Blood, MMB, CTI, Thrombocythemia, United Kingdom, Abdomen, Diagnosis, Oncology, Haematopoietic system, Skin, Medical device, Medical imaging, Pacritinib, Momelotinib, Ropeginterferon alfa-2b

LAS VEGAS, Aug. 30, 2023 /PRNewswire/ -- DelveInsight's Essential Thrombocythemia Market Insights report includes a comprehensive understanding of current treatment practices, essential thrombocythemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • These factors along with the expected launch of emerging therapies will boost the essential thrombocythemia market in the forecasted period.
  • As per DelveInsight analysts, total prevalent population of essential thrombocythemia in the 7MM was 240K in 2020.
  • Estimates observed that the age-group 60-80 years accounted for highest cases of essential thrombocythemia in the United States.
  • To know more about essential thrombocythemia treatment, visit @ Essential Thrombocythemia Treatment Drugs

Essential Thrombocythemia Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Imago BioSciences, Incyte, Karyopharm, Novartis, PharmaEssentia, Celgene, Kartos, Sierra Oncology

Retrieved on: 
Wednesday, August 30, 2023
GSK plc, Disease, Headache, Essential thrombocythemia, Bleeding, Prevalence, Conditional sentence, Hydroxycarbamide, Bone marrow, Genetic testing, Platelet, Petechia, Aspirin, Common, LAS, Bruise, Dizziness, Spleen, Novartis, Patient, Risk, Physiology, Plateletpheresis, Blood, MMB, CTI, Thrombocythemia, United Kingdom, Abdomen, Diagnosis, Oncology, Haematopoietic system, Skin, Medical device, Medical imaging, Pacritinib, Momelotinib, Ropeginterferon alfa-2b

LAS VEGAS, Aug. 30, 2023 /PRNewswire/ -- DelveInsight's Essential Thrombocythemia Market Insights report includes a comprehensive understanding of current treatment practices, essential thrombocythemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • These factors along with the expected launch of emerging therapies will boost the essential thrombocythemia market in the forecasted period.
  • As per DelveInsight analysts, total prevalent population of essential thrombocythemia in the 7MM was 240K in 2020.
  • Estimates observed that the age-group 60-80 years accounted for highest cases of essential thrombocythemia in the United States.
  • To know more about essential thrombocythemia treatment, visit @ Essential Thrombocythemia Treatment Drugs

CTI BioPharma Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022
Janus, Society, Ruxolitinib, Nasdaq, Pacritinib, Thrombocytopenia, Platelet, Data analysis, Annual general meeting, Operating cost, Bleeding, ID, Investment, Myeloproliferative neoplasm, ASH, Hematology-Oncology and Stem Cell Transplantation Research Center, Primary myelofibrosis, Vera, CTI, Growth, Galena Biopharma, FLT3, ALK2, Webcast, JAK2, Anemia, CTIC, Patient, Mastocytosis, Telephone, JAK1, BID, Haematopoiesis, SOHO, Safety, Syndrome, Cytokine, FDA, Pharmaceutical industry, ACVR1

SEATTLE, Nov. 7, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter ended September 30, 2022.

Key Points: 
  • ET
    SEATTLE, Nov. 7, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter ended September 30, 2022.
  • "In the third quarter, CTI continued to make strong progress with the U.S. commercial launch of VONJO, delivering net revenue of $18.2 million, a 48% increase in sales compared to the second quarter.
  • CTI will host a conference call and webcast to review its third quarter 2022 financial results and provide an update on business activities today, November 7, 2022, at 4:30 p.m.
  • "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions.

CTI BioPharma Announces Oral Presentation at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition

Retrieved on: 
Thursday, November 3, 2022
Janus, FDA, CTIC, FLT3, JAK2, Vera, Syndrome, ALK2, Ruxolitinib, JAK1, Society, Haematopoiesis, Patient, Company, ASH, Exposition, Primary myelofibrosis, Pacritinib, Myeloproliferative neoplasm, Acquisition, Mastocytosis, Platelet, Cytokine, Thrombocytopenia, Nasdaq, CTI, Pharmaceutical industry

SEATTLE, Nov. 3, 2022 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation and two poster presentations from the Company's pacritinib program at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in New Orleans, Louisiana and virtually December 10-13, 2022.

Key Points: 
  • SEATTLE, Nov. 3, 2022 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation and two poster presentations from the Company's pacritinib program at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in New Orleans, Louisiana and virtually December 10-13, 2022.
  • The details of the oral presentation are as follows:
    Session Name: 634.
  • Myeloproliferative Syndromes: Clinical and Epidemiological: Towards Personalized Medicine in Myeloproliferative Neoplasms and Mastocytosis: New and Repurposed Drugs for Unmet Clinical Needs
    The details of the poster presentations are as follows:
    Session Name: 631.
  • VONJO is a registered trademark of CTI BioPharma Corp.

CTI BioPharma Announces Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Tuesday, May 10, 2022
Janus, Thrombocytopenia, ASCO, Cytokine, Pacritinib, TYK2, Nasdaq, Haematopoiesis, CSF1R, JAK2, Company, JAK3, JAK1, FMS, Primary myelofibrosis, Patient, Vera, American Society of Clinical Oncology, FDA, CTI, Ruxolitinib, Society, CTIC, CD135, FLT3, Annual general meeting, Acquisition, Platelet, Pharmaceutical industry

SEATTLE, May 10, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced one poster presentation from the Company's pacritinib program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago and virtually, June 3-7, 2021.

Key Points: 
  • SEATTLE, May 10, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced one poster presentation from the Company's pacritinib program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago and virtually, June 3-7, 2021.
  • Pacritinib exhibits inhibitory activity against additional cellular kinases (such as CSF1R and IRAK1), the clinical relevance of which is unknown.
  • CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
  • VONJOTM is a trademark of CTI BioPharma Corp.

CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

Retrieved on: 
Tuesday, March 1, 2022
Janus, Hematology, TYK2, Pneumonia, JAK3, Mount Sinai, Population, HIV disease progression rates, Heart, Webcast, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Peripheral edema, BAT, Bleeding, Toxicity, Fever, Haematopoiesis, Diarrhea, Associate professor, ID, CTI, JAK1, Cytokine, CTIC, Nausea, FMS, Vera, Disease, BD, CD135, DRI, Food, CSF1R, Acquisition, FLT3, Ruxolitinib, Caregiver, Cytopenia, Skin, FDA, Primary myelofibrosis, Platelet, Nasdaq, BID, Thrombocytopenia, Patient, Anemia, Pacritinib, Icahn School of Medicine at Mount Sinai, Oncology, JAK2, Pharmaceutical industry, Medicine

The accelerated approval is based on efficacy results from the pivotal Phase 3 PERSIST-2 study of VONJO in patients with myelofibrosis (platelet counts less than or equal to 100 109/L).

Key Points: 
  • The accelerated approval is based on efficacy results from the pivotal Phase 3 PERSIST-2 study of VONJO in patients with myelofibrosis (platelet counts less than or equal to 100 109/L).
  • As part of the accelerated approval, CTI is required to describe a clinical benefit in a confirmatory trial.
  • CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
  • "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions.

CTI BioPharma Presents Data from Pacritinib Program at the 63rd American Society of Hematology Meeting

Retrieved on: 
Monday, December 13, 2021
JAK, FDA, Biopharma LLC, IRAK1, Thrombocytopenia, Patient, JAK1, CTI, MTSS, Platelet, CTIC, Ruxolitinib, PDUFA, BAT, Society, Pacritinib, SVR, Exposition, Safety, Nasdaq, ASH, Pharmaceutical industry

SEATTLE, Dec. 13, 2021 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) announced five scientific poster presentations on the pacritinib clinical program at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held as a hybrid (virtual and live) meeting in Atlanta, Georgia, December 11-14, 2021.

Key Points: 
  • SEATTLE, Dec. 13, 2021 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) announced five scientific poster presentations on the pacritinib clinical program at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held as a hybrid (virtual and live) meeting in Atlanta, Georgia, December 11-14, 2021.
  • While many patients in the BAT arm (45%) received ruxolitinib, an analysis of the comparison between pacritinib and ruxolitinib has not been previously performed.
  • After receiving pacritinib on an original clinical trial, 75 patients continued to receive pacritinib on a compassionate use basis.
  • "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions.

CTI BioPharma Announces Presentations at the 63rd American Society of Hematology Meeting

Retrieved on: 
Thursday, November 4, 2021
CLL, Myelodysplastic syndrome, Exposition, CSF1R, Leukemia, MDS, Impact, CMML, Moderate, FLT, CTI, Pancreatic serous cystadenoma, Pacritinib, ASH, Lymphoma, Primary myelofibrosis, Thrombocytopenia, Company, JAK2, Chronic myelomonocytic leukemia, JAK, CTIC, Acute myeloid leukemia, JAK1, Chronic lymphocytic leukemia, Nasdaq, AML, Acquisition, Society, Ruxolitinib, Enzyme, Pharmaceutical industry

SEATTLE, Nov. 4, 2021 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) today announced five poster presentations from the Company's pacritinib program at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held virtually and in Atlanta, Georgia, December 11-14, 2021.

Key Points: 
  • SEATTLE, Nov. 4, 2021 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) today announced five poster presentations from the Company's pacritinib program at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held virtually and in Atlanta, Georgia, December 11-14, 2021.
  • Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma.
  • We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need.
  • In particular, we are focused on developing and commercializing pacritinib, our product candidate currently in active late-stage development.

CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial

Retrieved on: 
Monday, June 1, 2020
Immunology, Ethers, Pacritinib, Pyrrolidines, Janus kinase 2, Interleukin-1 receptor associated kinase, Cytokine, Branches of biology

SEATTLE, June 1, 2020 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19.

Key Points: 
  • SEATTLE, June 1, 2020 /PRNewswire/ --CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19.
  • "Initiation of patient enrollment in the PRE-VENT Phase 3 trial is an important step for CTI as we work towards providing a new therapeutic option for patients with severe COVID-19," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI BioPharma.
  • As a JAK2/IRAK-1 inhibitor, pacritinib may ameliorate the effects of cytokine storm via inhibition of IL-6 and IL-1 signaling.
  • "CTI BioPharma" and theCTI BioPharmalogo are registered trademarks or trademarks ofCTI BioPharma Corp.in various jurisdictions.